{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Evolving concepts in the treatment of relapsing multiple sclerosis",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "NCIT": "^C\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "ms/comi2016.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Interferon beta was the ﬁrst drug to be approved for relapsing-remitting multiple sclerosis.[3–5] It is a naturally occurring cytokine with anti-inﬂammatory properties that induces transcription of many genes by binding to a speciﬁc cell-surface receptor; the overall eﬀect is an anti-inﬂ ammatory response. [17]",
      "key": "3a4b5aae3edff93ae6962ec56cfcd8de",
      "line": 80,
      "relation": "decreases",
      "source": 29,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Interferon beta was the ﬁrst drug to be approved for relapsing-remitting multiple sclerosis.[3–5] It is a naturally occurring cytokine with anti-inﬂammatory properties that induces transcription of many genes by binding to a speciﬁc cell-surface receptor; the overall eﬀect is an anti-inﬂ ammatory response. [17]",
      "key": "69f1d5961aaaac8b200ac1dbe628b367",
      "line": 81,
      "relation": "isA",
      "source": 29,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Interferon beta is also associated with ﬂu-like symptoms, but serious adverse events occur rarely.[3–5]",
      "key": "4b3503d31fa88f47e9fae41df8239571",
      "line": 87,
      "relation": "increases",
      "source": 29,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "An Italian observational study in patients with relapsing-remitting multiple sclerosis showed that interferon beta treatment decreased the rate of conversion to the secondary progressive phase and the proportion of patients reaching irreversible disability (deﬁned as reaching the milestone of EDSS score of 4 or 6) compared with untreated patients.[75]",
      "key": "a4a9f74724321a3d454b70c4200f2ae0",
      "line": 285,
      "relation": "decreases",
      "source": 29,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Inﬂammatory activity—the target of all the approved disease-modifying therapies in relapsing multiple sclerosis—from an impairment of adaptive peripheral immunity [65,66] predominates in the initial phase of the disease and tends to decline with the evolution of the disease, when other pathogenic mechanisms mostly related to innate immunity take a major role inside the CNS.",
      "key": "8af90d94f743658656e053824bb3f58a",
      "line": 277,
      "relation": "decreases",
      "source": 62,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        },
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Inﬂammatory activity—the target of all the approved disease-modifying therapies in relapsing multiple sclerosis—from an impairment of adaptive peripheral immunity [65,66] predominates in the initial phase of the disease and tends to decline with the evolution of the disease, when other pathogenic mechanisms mostly related to innate immunity take a major role inside the CNS.",
      "key": "026444a746a8c5ada371760e21e87631",
      "line": 279,
      "relation": "increases",
      "source": 62,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Glatiramer acetate can cause a self-limiting acute systemic post-injection reaction with palpitations, chest tightness, and anxiety.",
      "key": "1ad65c18398417d859fd026d2797762f",
      "line": 92,
      "relation": "increases",
      "source": 15,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Glatiramer acetate can cause a self-limiting acute systemic post-injection reaction with palpitations, chest tightness, and anxiety.",
      "key": "35bb3afc6a7a65c7976b4bc1f27d2442",
      "line": 93,
      "relation": "increases",
      "source": 15,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Glatiramer acetate can cause a self-limiting acute systemic post-injection reaction with palpitations, chest tightness, and anxiety.",
      "key": "6c8a6f36785f2a114cd5736bfcd66522",
      "line": 94,
      "relation": "increases",
      "source": 15,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Glatiramer acetate can cause a self-limiting acute systemic post-injection reaction with palpitations, chest tightness, and anxiety.",
      "key": "215cf4b4c686fd376cc519b499aa9a46",
      "line": 95,
      "relation": "increases",
      "source": 15,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Teriﬂunomide is the active metabolite of leﬂunomide, a dihydroorotate dehydrogenase inhibitor that inhibits the proliferation of autoreactive B and T cells.",
      "key": "39299fe188a5a477357aa11721860d40",
      "line": 100,
      "relation": "increases",
      "source": 9,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Teriﬂunomide is the active metabolite of leﬂunomide, a dihydroorotate dehydrogenase inhibitor that inhibits the proliferation of autoreactive B and T cells.",
      "key": "b665024c04b4eb612951553f1b85514d",
      "line": 101,
      "relation": "isA",
      "source": 9,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        },
        "MeSHAnatomy": {
          "B-Lymphocytes": true,
          "T-Lymphocytes": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Teriﬂunomide is the active metabolite of leﬂunomide, a dihydroorotate dehydrogenase inhibitor that inhibits the proliferation of autoreactive B and T cells.",
      "key": "8734ef452b0273b3ac4f1f4c4f81dc44",
      "line": 103,
      "relation": "decreases",
      "source": 9,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Additionally, teriﬂunomide has immunomodulatory properties by inducing a shift to an anti-inﬂammatory cytokine proﬁle and a switch in the class of immunoglobulins.[24]",
      "key": "3fc4754460a8da3653b5817e6527c328",
      "line": 109,
      "relation": "increases",
      "source": 13,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Additionally, teriﬂunomide has immunomodulatory properties by inducing a shift to an anti-inﬂammatory cytokine proﬁle and a switch in the class of immunoglobulins.[24]",
      "key": "56098c046710e10a2d7cbb941276f4c9",
      "line": 110,
      "relation": "increases",
      "source": 13,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse eﬀects observed with teriﬂunomide are headache, increased liver enzymes, diarrhoea, hair thinning, and nausea.[11,12,25]",
      "key": "3eb873e94277f868e80ed21d0eb98cfa",
      "line": 115,
      "relation": "increases",
      "source": 13,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse eﬀects observed with teriﬂunomide are headache, increased liver enzymes, diarrhoea, hair thinning, and nausea.[11,12,25]",
      "key": "b7d73695e8930583abef88ee5a5bd4c7",
      "line": 116,
      "object": {
        "location": {
          "name": "Liver",
          "namespace": "MESH"
        }
      },
      "relation": "increases",
      "source": 13,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse eﬀects observed with teriﬂunomide are headache, increased liver enzymes, diarrhoea, hair thinning, and nausea.[11,12,25]",
      "key": "0ddd2fca02c8d340b9ee3a7313622368",
      "line": 117,
      "relation": "increases",
      "source": 13,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse eﬀects observed with teriﬂunomide are headache, increased liver enzymes, diarrhoea, hair thinning, and nausea.[11,12,25]",
      "key": "2356aa238b74ed0a090d60aaf283678a",
      "line": 118,
      "relation": "increases",
      "source": 13,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse eﬀects observed with teriﬂunomide are headache, increased liver enzymes, diarrhoea, hair thinning, and nausea.[11,12,25]",
      "key": "aaf6a52d0b0e58e5496ef68bd89a524b",
      "line": 119,
      "relation": "increases",
      "source": 13,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "ddad5671bf8ac72baad76e8f7a4d73ba",
      "line": 124,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 2,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "baa54fd86825295ba0e92ffba269e78f",
      "line": 126,
      "relation": "isA",
      "source": 2,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "4202e201e0b3fd8c18db62c85d75ab42",
      "line": 127,
      "relation": "decreases",
      "source": 2,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "51f48ed6fe4541577c649835aa9fb235",
      "line": 130,
      "relation": "decreases",
      "source": 2,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "267d88523b14a6640d36420b218df901",
      "line": 131,
      "relation": "decreases",
      "source": 2,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Flushing and gastrointestinal symptoms are the most frequent side-eﬀects of dimethyl fumarate;[13,14] they have been reported in 40% and 30% of patients, respectively, but tend to decrease after the ﬁrst 2–3 months and lead to an interruption of the treatment in few patients.",
      "key": "ca2c2cb8a7fe1bf40dd12642aac8eb0c",
      "line": 136,
      "relation": "increases",
      "source": 2,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Flushing and gastrointestinal symptoms are the most frequent side-eﬀects of dimethyl fumarate;[13,14] they have been reported in 40% and 30% of patients, respectively, but tend to decrease after the ﬁrst 2–3 months and lead to an interruption of the treatment in few patients.",
      "key": "0a90ea997ef7b5787bd788624aba0cd9",
      "line": 137,
      "relation": "increases",
      "source": 2,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "After the approval of dimethyl fumarate, a few cases of progressive multifocal leukoencephalopathy were reported during treatment.",
      "key": "916485f2c8d21e4c61ddee1f691db0ca",
      "line": 142,
      "relation": "increases",
      "source": 2,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "95d018cbbebc5bf4fb6efeef5fa59a91",
      "line": 125,
      "object": {
        "effect": {
          "name": "antioxidant activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 33,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "1a544aaeb457b4d3da6124ebe31fbc9a",
      "line": 128,
      "relation": "increases",
      "source": 34,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Dimethyl fumarate has a dual eﬀect. By activating the transcription factor nuclear-factor-E2-related factor 2 (Nrf2), it has an antioxidant eﬀect, and through inhibition of the transcription factor nuclear-factor κB it reduces the release of inﬂammatory cytokines.[28] ",
      "key": "4d70ff5e3efabd45dd3e1263c8384c63",
      "line": 129,
      "relation": "increases",
      "source": 18,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Fingolimod is a sphingosine 1-phosphate analogue that acts as a functional antagonist of sphingosine 1-phosphate receptors.",
      "key": "da32171dd8de46b724229a0fd7b475ae",
      "line": 147,
      "relation": "decreases",
      "source": 25,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "After oral administration, ﬁngolimod is immediately phosphorylated and bound to the sphingosine 1-phosphate receptor, which is stimulated and subsequently internalised and degraded.",
      "key": "af8bf1836fa384dd1b8b13f42f74ebcd",
      "line": 152,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 25,
      "target": 36
    },
    {
      "key": "02dc2a65521964be0f3de36cbceb72d3",
      "relation": "partOf",
      "source": 8,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "In a head-to head comparison with intramuscular interferon beta-1a 30 μg weekly, oral ﬁngolimod reduced the annualised relapse rate by 52%.[32]",
      "key": "17b2a27e3d8d4b507b2a6bc359da6724",
      "line": 157,
      "relation": "decreases",
      "source": 8,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "After the ﬁrst dose is administered, some patients develop symptomatic bradycardia or atrioventricular conduction block (fewer than 2%).[33]",
      "key": "cb3f90137dc90627e91e59bbf914d088",
      "line": 163,
      "relation": "increases",
      "source": 8,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "After the ﬁrst dose is administered, some patients develop symptomatic bradycardia or atrioventricular conduction block (fewer than 2%).[33]",
      "key": "91c7592dc82814e64daf4dc59127b760",
      "line": 164,
      "relation": "increases",
      "source": 8,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Other adverse events include macula oedema, elevated liver function tests, and increased risk of infections.[34]",
      "key": "f0f32ebce12123fccc726c772d7ffc5e",
      "line": 170,
      "relation": "increases",
      "source": 8,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Other adverse events include macula oedema, elevated liver function tests, and increased risk of infections.[34]",
      "key": "643f03e66c3f9c393788783418a02bac",
      "line": 171,
      "relation": "increases",
      "source": 8,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Other adverse events include macula oedema, elevated liver function tests, and increased risk of infections.[34]",
      "key": "e8c0390d79ed8ddf770b7a9499c3b987",
      "line": 172,
      "relation": "increases",
      "source": 8,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Speciﬁcally, rare fatal herpes simplex encephalitis and disseminated varicella zoster infections have occurred; thus a varicella zoster virus antibody test is mandatory before starting ﬁngolimod and, if necessary, vaccination is required.",
      "key": "a54db0ace50176614e3f14c13d3b8f29",
      "line": 178,
      "relation": "increases",
      "source": 8,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Speciﬁcally, rare fatal herpes simplex encephalitis and disseminated varicella zoster infections have occurred; thus a varicella zoster virus antibody test is mandatory before starting ﬁngolimod and, if necessary, vaccination is required.",
      "key": "c812220396692df7c4dbce5e4cb002ab",
      "line": 179,
      "relation": "increases",
      "source": 8,
      "target": 48
    },
    {
      "key": "4ed6a94c05a87e96d3bbcc95cc9f6ff9",
      "relation": "partOf",
      "source": 36,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Rare cases of opportunistic infections, cryptococcical meningitis, and progressive multifocal leukoencephalopathy, even without previous exposure to natalizumab, have been reported.[35]",
      "key": "220d428366c0e3574b0d8d9e3b40475a",
      "line": 184,
      "relation": "increases",
      "source": 10,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Rare cases of opportunistic infections, cryptococcical meningitis, and progressive multifocal leukoencephalopathy, even without previous exposure to natalizumab, have been reported.[35]",
      "key": "bcdccba506c15cab92779d55983d5cab",
      "line": 185,
      "relation": "increases",
      "source": 10,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Rare cases of opportunistic infections, cryptococcical meningitis, and progressive multifocal leukoencephalopathy, even without previous exposure to natalizumab, have been reported.[35]",
      "key": "9e7c0e3a9517bf47cafa647994264200",
      "line": 186,
      "relation": "increases",
      "source": 10,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Natalizumab is a humanised therapeutic monoclonal antibody that acts by blocking α-4 integrin, a component of the very late antigen (VLA)-4 present on lymphocytes, and by inhibiting the interaction between VLA4 and the ligand VCAM, preventing lymphocytes from entering the CNS across the blood–brain barrier.[36]",
      "key": "818cf641b5a361de00d848475dfecc83",
      "line": 191,
      "relation": "isA",
      "source": 10,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Natalizumab is a humanised therapeutic monoclonal antibody that acts by blocking α-4 integrin, a component of the very late antigen (VLA)-4 present on lymphocytes, and by inhibiting the interaction between VLA4 and the ligand VCAM, preventing lymphocytes from entering the CNS across the blood–brain barrier.[36]",
      "key": "c20a136e77a5c01276733679850b4c03",
      "line": 192,
      "relation": "decreases",
      "source": 10,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Natalizumab is a humanised therapeutic monoclonal antibody that acts by blocking α-4 integrin, a component of the very late antigen (VLA)-4 present on lymphocytes, and by inhibiting the interaction between VLA4 and the ligand VCAM, preventing lymphocytes from entering the CNS across the blood–brain barrier.[36]",
      "key": "43929e73d1eb148bfff6f0293d8aea23",
      "line": 193,
      "relation": "decreases",
      "source": 10,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Natalizumab is a humanised therapeutic monoclonal antibody that acts by blocking α-4 integrin, a component of the very late antigen (VLA)-4 present on lymphocytes, and by inhibiting the interaction between VLA4 and the ligand VCAM, preventing lymphocytes from entering the CNS across the blood–brain barrier.[36]",
      "key": "35809e9dd4890ffeac77623575a7e9ef",
      "line": 194,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Blood",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Brain",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 10,
      "target": 19
    },
    {
      "key": "49477ebdb167f5606cb9a1dd31c8ff6c",
      "relation": "partOf",
      "source": 35,
      "target": 27
    },
    {
      "key": "5c1b0c58b81ca6baf15a80f6e14bed4a",
      "relation": "partOf",
      "source": 38,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Alemtuzumab is a humanised monoclonal antibody directed against CD52, which is present on the surface of lymphocytes and monocytes. After administering alemtuzumab, 12 mg daily for 5 consecutive days, a long-lasting depletion of B and T cells occurs.",
      "key": "4631548ea935ed4bcff1b461a58e13a8",
      "line": 199,
      "relation": "isA",
      "source": 6,
      "target": 37
    },
    {
      "key": "a3e2a5ae4df24b5414c0de6932d2074d",
      "relation": "partOf",
      "source": 6,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Alemtuzumab is a humanised monoclonal antibody directed against CD52, which is present on the surface of lymphocytes and monocytes. After administering alemtuzumab, 12 mg daily for 5 consecutive days, a long-lasting depletion of B and T cells occurs.",
      "key": "5b0285ad8cd856aa0316bbdc115405c9",
      "line": 200,
      "relation": "increases",
      "source": 6,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Alemtuzumab is a humanised monoclonal antibody directed against CD52, which is present on the surface of lymphocytes and monocytes. After administering alemtuzumab, 12 mg daily for 5 consecutive days, a long-lasting depletion of B and T cells occurs.",
      "key": "95509c7592cc076180be76a365015df3",
      "line": 202,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 6,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Alemtuzumab is a humanised monoclonal antibody directed against CD52, which is present on the surface of lymphocytes and monocytes. After administering alemtuzumab, 12 mg daily for 5 consecutive days, a long-lasting depletion of B and T cells occurs.",
      "key": "0ff5d8b228002cabd1c6610da0d9b59e",
      "line": 203,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 6,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "In a comparative trial with interferon beta-1a, alemtuzumab signiﬁcantly reduced the annualised relapse rate and reduced a conﬁrmed worsening of multiple sclerosis.[15,16]",
      "key": "7bbbb92410f91c552c76241f73359004",
      "line": 208,
      "relation": "decreases",
      "source": 6,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "In a comparative trial with interferon beta-1a, alemtuzumab signiﬁcantly reduced the annualised relapse rate and reduced a conﬁrmed worsening of multiple sclerosis.[15,16]",
      "key": "7056df2cdf69692f73d82052d9947318",
      "line": 209,
      "relation": "decreases",
      "source": 6,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse event with alemtuzumab therapy is infusion reaction, which occurs in most patients but can be substantially reduced by pretreatment with corticosteroids and antihistamines.",
      "key": "8baba3f831861389fc3a0cc73ffb982d",
      "line": 214,
      "relation": "increases",
      "source": 6,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Herpetic and fungal infections can also develop; a prophylactic treatment with acyclovir is required for 1 month after each infusion.[49]",
      "key": "04f35630fb08cd51d057da2a47792ceb",
      "line": 222,
      "relation": "increases",
      "source": 6,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Herpetic and fungal infections can also develop; a prophylactic treatment with acyclovir is required for 1 month after each infusion.[49]",
      "key": "4bfe6aa59614ba359bce0d317dfceb24",
      "line": 223,
      "relation": "increases",
      "source": 6,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "More than 30% of patients develop thyroid disorders, and immune thrombocytopenia occurs in 1–3% of patients.[49] Glomerulonephritis has been observed in 0·3% of patients.[15,16] Autoimmune disorders usually occur 2–3 years after the ﬁrst dose of alemtuzumab.[15,16]",
      "key": "bcc62a22b755cfc2b729547970d51a26",
      "line": 232,
      "relation": "increases",
      "source": 6,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "More than 30% of patients develop thyroid disorders, and immune thrombocytopenia occurs in 1–3% of patients.[49] Glomerulonephritis has been observed in 0·3% of patients.[15,16] Autoimmune disorders usually occur 2–3 years after the ﬁrst dose of alemtuzumab.[15,16]",
      "key": "8dd64a7045f15a36b7d64a89a5b9c962",
      "line": 233,
      "relation": "increases",
      "source": 6,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "More than 30% of patients develop thyroid disorders, and immune thrombocytopenia occurs in 1–3% of patients.[49] Glomerulonephritis has been observed in 0·3% of patients.[15,16] Autoimmune disorders usually occur 2–3 years after the ﬁrst dose of alemtuzumab.[15,16]",
      "key": "e06ab631d14614a35fdce9f8006b937d",
      "line": 234,
      "relation": "increases",
      "source": 6,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "More than 30% of patients develop thyroid disorders, and immune thrombocytopenia occurs in 1–3% of patients.[49] Glomerulonephritis has been observed in 0·3% of patients.[15,16] Autoimmune disorders usually occur 2–3 years after the ﬁrst dose of alemtuzumab.[15,16]",
      "key": "3ef20896907852e2ee8d720b1807c421",
      "line": 235,
      "relation": "increases",
      "source": 6,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "In a long-term follow-up study, alemtuzumab had a remarkably durable treatment eﬀect, and approximately half of patients did not require retreatment in a median 7 years of follow up.[92]",
      "key": "e92a40e49d0942a6fe2b294cd255d8f5",
      "line": 290,
      "relation": "decreases",
      "source": 6,
      "target": 62
    },
    {
      "key": "041418ef51f55fef5a0b70b4723ffa43",
      "relation": "partOf",
      "source": 28,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "A natural history study conﬁrmed that multiple sclerosis is a serious disease; approximately 80% of patients develop severe disability 54 and life expectancy is reduced by 10 years.[55]",
      "key": "feb99c09207f29b2df4826612e6ff661",
      "line": 265,
      "relation": "increases",
      "source": 40,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "A natural history study conﬁrmed that multiple sclerosis is a serious disease; approximately 80% of patients develop severe disability 54 and life expectancy is reduced by 10 years.[55]",
      "key": "767301077734f0299f742a3cd64d9d8d",
      "line": 266,
      "relation": "decreases",
      "source": 40,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Both MRI [57,58] and optical coherence tomography studies [59,60] have provided clear evidence that early axonal losses already occur in patients with a ﬁrst episode of multiple sclerosis (clinically isolated syndrome), and even earlier in radiologically isolated syndromes (patients without any clinical symptoms).[61]",
      "key": "d88e0b4c7657181fd9851da2b598f55c",
      "line": 272,
      "relation": "increases",
      "source": 40,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse event with alemtuzumab therapy is infusion reaction, which occurs in most patients but can be substantially reduced by pretreatment with corticosteroids and antihistamines.",
      "key": "d7e0ff52a44b76e793a9302ac284e02b",
      "line": 215,
      "relation": "decreases",
      "source": 4,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The most frequent adverse event with alemtuzumab therapy is infusion reaction, which occurs in most patients but can be substantially reduced by pretreatment with corticosteroids and antihistamines.",
      "key": "4791999e4f9d14feffc90e0efd5ce75a",
      "line": 216,
      "relation": "decreases",
      "source": 16,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Herpetic and fungal infections can also develop; a prophylactic treatment with acyclovir is required for 1 month after each infusion.[49]",
      "key": "a60dff5187079e5684f9ef8b00b8cb33",
      "line": 225,
      "relation": "decreases",
      "source": 5,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Herpetic and fungal infections can also develop; a prophylactic treatment with acyclovir is required for 1 month after each infusion.[49]",
      "key": "26c00d65eafc11a80466e29aecb2e957",
      "line": 226,
      "relation": "decreases",
      "source": 5,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Daclizumab, already approved in the USA, is a monoclonal antibody acting as an interleukin 2 inhibitor.[51] In the phase 3 trial, monthly subcutaneous administration of daclizumab signiﬁcantly decreased the annualised relapse rate by 45% compared with 30 μg interferon beta-1a.51",
      "key": "d26a03b39dd8f55e300202cf7fed291b",
      "line": 240,
      "relation": "isA",
      "source": 7,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Daclizumab, already approved in the USA, is a monoclonal antibody acting as an interleukin 2 inhibitor.[51] In the phase 3 trial, monthly subcutaneous administration of daclizumab signiﬁcantly decreased the annualised relapse rate by 45% compared with 30 μg interferon beta-1a.51",
      "key": "be093040e7a676e71e41ca9292434fbe",
      "line": 241,
      "relation": "decreases",
      "source": 7,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Daclizumab, already approved in the USA, is a monoclonal antibody acting as an interleukin 2 inhibitor.[51] In the phase 3 trial, monthly subcutaneous administration of daclizumab signiﬁcantly decreased the annualised relapse rate by 45% compared with 30 μg interferon beta-1a.51",
      "key": "092ae24eb668ad0624a33c7803bd68e3",
      "line": 242,
      "relation": "decreases",
      "source": 7,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Ocrelizumab is a humanised monoclonal antibody directed against CD20.",
      "key": "922ad701d52d83945bd6fc59c7178f18",
      "line": 247,
      "relation": "isA",
      "source": 11,
      "target": 37
    },
    {
      "key": "90c467f6b8aecb8f8c44ae018d924372",
      "relation": "partOf",
      "source": 11,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Ocrelizumab is a humanised monoclonal antibody directed against CD20.",
      "key": "42a8f747d8231dd1d05fd44d0dbbb286",
      "line": 248,
      "relation": "increases",
      "source": 11,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Ocrelizumab signiﬁcantly reduced the annualised relapse rate by 46% and 47% respectively.",
      "key": "3bf84a5c33e0e19dcbdb3f08917f4e9f",
      "line": 253,
      "relation": "decreases",
      "source": 11,
      "target": 73
    },
    {
      "key": "1f8facc30e111b5088dc41dec77763fe",
      "relation": "partOf",
      "source": 32,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The eﬃcacy of ocrelizumab is supported also by clinical experience with rituximab, a chimeric anti-CD20 monoclonal antibody, in multiple sclerosis.[53]",
      "key": "a07e8901f365408dde0e8798f0d28c3c",
      "line": 258,
      "relation": "isA",
      "source": 12,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "The eﬃcacy of ocrelizumab is supported also by clinical experience with rituximab, a chimeric anti-CD20 monoclonal antibody, in multiple sclerosis.[53]",
      "key": "a5ef421f22c3909fbc7f0af79fa85d4b",
      "line": 259,
      "relation": "increases",
      "source": 12,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "relapsing-remitting multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Leboyer M",
          "Pape K",
          "Tamouza R",
          "Zipp F"
        ],
        "date": "2019-06-01",
        "db": "PubMed",
        "db_id": "30988501",
        "db_name": "Immunoneuropsychiatry - novel perspectives on brain disorders.",
        "first": "Pape K",
        "journal": "Nature reviews. Neurology",
        "last": "Zipp F",
        "pages": "317-328",
        "volume": "15"
      },
      "evidence": "Both MRI [57,58] and optical coherence tomography studies [59,60] have provided clear evidence that early axonal losses already occur in patients with a ﬁrst episode of multiple sclerosis (clinically isolated syndrome), and even earlier in radiologically isolated syndromes (patients without any clinical symptoms).[61]",
      "key": "c2ebd9f64168f800d7f287857e598441",
      "line": 271,
      "relation": "increases",
      "source": 55,
      "target": 45
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor\")",
      "concept": {
        "name": "EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "6d3a2788f4ba9504af909b1b2a9c790f"
    },
    {
      "bel": "a(CHEBI:\"anti-inflammatory agent\")",
      "concept": {
        "name": "anti-inflammatory agent",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0ff538621f3d71a90210e2df925f4a0f"
    },
    {
      "bel": "a(CHEBI:\"dimethyl fumarate\")",
      "concept": {
        "name": "dimethyl fumarate",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1dfb50778023775ca326ed078cc1dd5b"
    },
    {
      "bel": "a(CHEBI:antioxidant)",
      "concept": {
        "name": "antioxidant",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "238ed17f4af316c445be0c3793191be8"
    },
    {
      "bel": "a(CHEBI:corticosteroid)",
      "concept": {
        "name": "corticosteroid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a468686acdbd9b5763eec60c73e99320"
    },
    {
      "bel": "a(DRUGBANK:Acyclovir)",
      "concept": {
        "name": "Acyclovir",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "289799ec58902ff5e7d9a1c3d901e385"
    },
    {
      "bel": "a(DRUGBANK:Alemtuzumab)",
      "concept": {
        "name": "Alemtuzumab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "a9e8e900a7436b53db2fd959d58476e9"
    },
    {
      "bel": "a(DRUGBANK:Daclizumab)",
      "concept": {
        "name": "Daclizumab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "56dacc41da179396742f4a397a01b5a4"
    },
    {
      "bel": "a(DRUGBANK:Fingolimod)",
      "concept": {
        "name": "Fingolimod",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "de33bded27be2c6871c8e342da56fc38"
    },
    {
      "bel": "a(DRUGBANK:Leflunomide)",
      "concept": {
        "name": "Leflunomide",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "58c2eba1e122ed0b03a4665b85fb9d7c"
    },
    {
      "bel": "a(DRUGBANK:Natalizumab)",
      "concept": {
        "name": "Natalizumab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "aa5b6e671b82a62bbe1c8f71f964055a"
    },
    {
      "bel": "a(DRUGBANK:Ocrelizumab)",
      "concept": {
        "name": "Ocrelizumab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "760ab0de7e8320f04fddfa890b4ab291"
    },
    {
      "bel": "a(DRUGBANK:Rituximab)",
      "concept": {
        "name": "Rituximab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "8afe8a1197ea2723505bd32a9b561772"
    },
    {
      "bel": "a(DRUGBANK:Teriflunomide)",
      "concept": {
        "name": "Teriflunomide",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "eeb4392b68c3f16b9784fb1a82d79846"
    },
    {
      "bel": "a(MESH:\"B-Lymphocytes\")",
      "concept": {
        "name": "B-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "f58463c9771eaea79cce530465284035"
    },
    {
      "bel": "a(MESH:\"Glatiramer Acetate\")",
      "concept": {
        "name": "Glatiramer Acetate",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "b04c825e3baa4d90dcd627d862c6ed6e"
    },
    {
      "bel": "a(MESH:\"Histamine Antagonists\")",
      "concept": {
        "name": "Histamine Antagonists",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1302842071bd1185f666faceb62eaf15"
    },
    {
      "bel": "a(MESH:\"T-Lymphocytes\")",
      "concept": {
        "name": "T-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "04840e346c8f8e46d6d4e5ed8f1b84c5"
    },
    {
      "bel": "a(MESH:Cytokines)",
      "concept": {
        "name": "Cytokines",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "0d3c01297f25a34285f54b350178a231"
    },
    {
      "bel": "a(MESH:Lymphocytes)",
      "concept": {
        "name": "Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "05994a861f52857ee7dd98e839952695"
    },
    {
      "bel": "bp(MESH:\"Adaptive Immunity\")",
      "concept": {
        "name": "Adaptive Immunity",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "79a63eee9cdc077e74d464de3d03ae28"
    },
    {
      "bel": "bp(MESH:\"Cell Proliferation\")",
      "concept": {
        "name": "Cell Proliferation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "242afa77159d7404a9f4d58d3c0e0c4e"
    },
    {
      "bel": "bp(MESH:\"Immunoglobulin Class Switching\")",
      "concept": {
        "name": "Immunoglobulin Class Switching",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "68ccdeef8806ed17acfbcb7e94034dbd"
    },
    {
      "bel": "bp(MESH:Immunomodulation)",
      "concept": {
        "name": "Immunomodulation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "75cdd0405cf6f4cb7808a74072d94f6f"
    },
    {
      "bel": "complex(a(DRUGBANK:Alemtuzumab), p(HGNC:CD52))",
      "function": "Complex",
      "id": "ce9e212e74e341ba32e6cb258826e091",
      "members": [
        {
          "bel": "a(DRUGBANK:Alemtuzumab)",
          "concept": {
            "name": "Alemtuzumab",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "a9e8e900a7436b53db2fd959d58476e9"
        },
        {
          "bel": "p(HGNC:CD52)",
          "concept": {
            "name": "CD52",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "a170806da31931ea14f246775eee2d62"
        }
      ]
    },
    {
      "bel": "complex(a(DRUGBANK:Fingolimod), p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\"))",
      "function": "Complex",
      "id": "2741d3454539bb09faeb9b5795a36fe4",
      "members": [
        {
          "bel": "a(DRUGBANK:Fingolimod)",
          "concept": {
            "name": "Fingolimod",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "de33bded27be2c6871c8e342da56fc38"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\")",
          "concept": {
            "name": "Sphingosine 1-phosphate receptors",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "e1d36600ec3ae163d5c1f044a7eae6ee"
        }
      ]
    },
    {
      "bel": "complex(a(DRUGBANK:Ocrelizumab), p(HGNC:MS4A1))",
      "function": "Complex",
      "id": "b64c61c29d732910b421ef175c60772b",
      "members": [
        {
          "bel": "a(DRUGBANK:Ocrelizumab)",
          "concept": {
            "name": "Ocrelizumab",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "760ab0de7e8320f04fddfa890b4ab291"
        },
        {
          "bel": "p(HGNC:MS4A1)",
          "concept": {
            "name": "MS4A1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "ad9ecfa29e4d4968bbe05fc7d9ca9781"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:VCAM1), p(MESH:\"Receptors, Very Late Antigen\"))",
      "function": "Complex",
      "id": "6530ffa1b7f803c4a0b3659882845e0d",
      "members": [
        {
          "bel": "p(HGNC:VCAM1)",
          "concept": {
            "name": "VCAM1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1f8295903afe529c3261018587ec7a88"
        },
        {
          "bel": "p(MESH:\"Receptors, Very Late Antigen\")",
          "concept": {
            "name": "Receptors, Very Late Antigen",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "a7570504f6d8c6303eeeb4a8dc4f3257"
        }
      ]
    },
    {
      "bel": "p(HGNC:CD52)",
      "concept": {
        "name": "CD52",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a170806da31931ea14f246775eee2d62"
    },
    {
      "bel": "p(HGNC:IFNB1)",
      "concept": {
        "name": "IFNB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "187da957c4e0c092e01fc85dd9da5fa4"
    },
    {
      "bel": "p(HGNC:IL2)",
      "concept": {
        "name": "IL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "99fcd5fe54813ead0bd02d8a06f42173"
    },
    {
      "bel": "p(HGNC:ITGA4)",
      "concept": {
        "name": "ITGA4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5dd2353ec77585df3ddc7b475d39e72d"
    },
    {
      "bel": "p(HGNC:MS4A1)",
      "concept": {
        "name": "MS4A1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ad9ecfa29e4d4968bbe05fc7d9ca9781"
    },
    {
      "bel": "p(HGNC:NFE2L2)",
      "concept": {
        "name": "NFE2L2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7e8941fff5d3be67079854e55d40d075"
    },
    {
      "bel": "p(HGNC:NFKB1)",
      "concept": {
        "name": "NFKB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6e6f7419cc0edfa08d7d4c82eae0f4c4"
    },
    {
      "bel": "p(HGNC:VCAM1)",
      "concept": {
        "name": "VCAM1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1f8295903afe529c3261018587ec7a88"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\")",
      "concept": {
        "name": "Sphingosine 1-phosphate receptors",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "e1d36600ec3ae163d5c1f044a7eae6ee"
    },
    {
      "bel": "p(MESH:\"Antibodies, Monoclonal\")",
      "concept": {
        "name": "Antibodies, Monoclonal",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "981f47ac703582b8464d68d85dbaaa4d"
    },
    {
      "bel": "p(MESH:\"Receptors, Very Late Antigen\")",
      "concept": {
        "name": "Receptors, Very Late Antigen",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "a7570504f6d8c6303eeeb4a8dc4f3257"
    },
    {
      "bel": "p(MESH:Enzymes)",
      "concept": {
        "name": "Enzymes",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "a4f1227d29fe2fc8121bd45717a7bb58"
    },
    {
      "bel": "path(DOID:\"multiple sclerosis\")",
      "concept": {
        "name": "multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "828e65d53fe5c29b364f79cfd5304f90"
    },
    {
      "bel": "path(DOID:\"progressive multifocal leukoencephalopathy\")",
      "concept": {
        "name": "progressive multifocal leukoencephalopathy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "4f9b944390c450df4675270bc58f3417"
    },
    {
      "bel": "path(DOID:\"secondary progressive multiple sclerosis\")",
      "concept": {
        "name": "secondary progressive multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "38f0567d9ceb0ade6bf93de56a897396"
    },
    {
      "bel": "path(DOID:glomerulonephritis)",
      "concept": {
        "name": "glomerulonephritis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "159e21269061de6a732b149f758a44a2"
    },
    {
      "bel": "path(DOID:thrombocytopenia)",
      "concept": {
        "name": "thrombocytopenia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "4889adbd9fa6982383c8792ff36970b5"
    },
    {
      "bel": "path(HP:\"Axonal loss\")",
      "concept": {
        "name": "Axonal loss",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "ea3a3af52b70a2c9cf17028a2e14bb03"
    },
    {
      "bel": "path(HP:\"Chest tightness\")",
      "concept": {
        "name": "Chest tightness",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "8d5a5c3bb00cfa864b6b05f95eb31025"
    },
    {
      "bel": "path(HP:\"Herpes simplex encephalitis\")",
      "concept": {
        "name": "Herpes simplex encephalitis",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "0c999dcab51161e0b82167a92ab522e0"
    },
    {
      "bel": "path(HP:\"Severe varicella zoster infection\")",
      "concept": {
        "name": "Severe varicella zoster infection",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "276d998d95d7f801f746a0865835c641"
    },
    {
      "bel": "path(HP:Anxiety)",
      "concept": {
        "name": "Anxiety",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "d6ab1a2f6a8518ad589ac17df1148bbb"
    },
    {
      "bel": "path(HP:Bradycardia)",
      "concept": {
        "name": "Bradycardia",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "553b0a498b1adffca12cd87ef87299e4"
    },
    {
      "bel": "path(HP:Headache)",
      "concept": {
        "name": "Headache",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "a24ae0bd1e3980c71af01ddc357c55ad"
    },
    {
      "bel": "path(HP:Palpitations)",
      "concept": {
        "name": "Palpitations",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "6e15b3eeafacc7f9bc481727eb25ada8"
    },
    {
      "bel": "path(MESH:\"Atrioventricular Block\")",
      "concept": {
        "name": "Atrioventricular Block",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6950e36c26fe7841e14e36bba7bbe056"
    },
    {
      "bel": "path(MESH:\"Autoimmune Diseases\")",
      "concept": {
        "name": "Autoimmune Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0aeb632260f15842cdd2b5e3c4b15c15"
    },
    {
      "bel": "path(MESH:\"Demyelinating Diseases\")",
      "concept": {
        "name": "Demyelinating Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "fd58854d02026d9f5fa3d1ebdeaee004"
    },
    {
      "bel": "path(MESH:\"Gastrointestinal Diseases\")",
      "concept": {
        "name": "Gastrointestinal Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "65637db6fc27015bacce56a4e46e53f8"
    },
    {
      "bel": "path(MESH:\"Injection Site Reaction\")",
      "concept": {
        "name": "Injection Site Reaction",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "045dcc5771f375a42a9157926ebbec02"
    },
    {
      "bel": "path(MESH:\"Life Expectancy\")",
      "concept": {
        "name": "Life Expectancy",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0f5935b0a6ff8f7f6b20b35fe1461b96"
    },
    {
      "bel": "path(MESH:\"Liver Function Tests\")",
      "concept": {
        "name": "Liver Function Tests",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6b50fe411cb9b1460335a95419ff12ce"
    },
    {
      "bel": "path(MESH:\"Macular Edema\")",
      "concept": {
        "name": "Macular Edema",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "80ca6797d3e6c4899bacb3a8a4c4e013"
    },
    {
      "bel": "path(MESH:\"Meningitis, Cryptococcal\")",
      "concept": {
        "name": "Meningitis, Cryptococcal",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f994fa1416820606f92269628ded10d2"
    },
    {
      "bel": "path(MESH:\"Multiple Sclerosis, Relapsing-Remitting\")",
      "concept": {
        "name": "Multiple Sclerosis, Relapsing-Remitting",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1c041f3b0601eb83b8dfbcdcef015e03"
    },
    {
      "bel": "path(MESH:\"Opportunistic Infections\")",
      "concept": {
        "name": "Opportunistic Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4cd7863916d59583f665c234723fe690"
    },
    {
      "bel": "path(MESH:\"Stomatitis, Herpetic\")",
      "concept": {
        "name": "Stomatitis, Herpetic",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e3d83497f2e68e4ffeaff7ed10cf23fc"
    },
    {
      "bel": "path(MESH:\"Thyroid Diseases\")",
      "concept": {
        "name": "Thyroid Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "7073d142f7af080d45430f02ae811f97"
    },
    {
      "bel": "path(MESH:Alopecia)",
      "concept": {
        "name": "Alopecia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a3f6ab22b2c073151cd3721761fd2f8b"
    },
    {
      "bel": "path(MESH:Diarrhea)",
      "concept": {
        "name": "Diarrhea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "380392a07df61a122a0053ada328efb8"
    },
    {
      "bel": "path(MESH:Flushing)",
      "concept": {
        "name": "Flushing",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "07c4f43b0f8c387ce6814f806edd8263"
    },
    {
      "bel": "path(MESH:Infection)",
      "concept": {
        "name": "Infection",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "572a317d84677724217aff971083c770"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "path(MESH:Mycoses)",
      "concept": {
        "name": "Mycoses",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "290e33bae26092a975df357b5866b447"
    },
    {
      "bel": "path(MESH:Nausea)",
      "concept": {
        "name": "Nausea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "41e2b9e6454d4c63a3654236ce97040f"
    },
    {
      "bel": "path(MESH:Recurrence)",
      "concept": {
        "name": "Recurrence",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "aa96a379e06d692c47a017c1b23ad98f"
    },
    {
      "bel": "path(NCIT:C21007)",
      "concept": {
        "name": "C21007",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "567e9969f4afcd1025c406a11302125a"
    },
    {
      "bel": "path(NCIT:C78302)",
      "concept": {
        "name": "C78302",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "8eb89e7d3859857788d0b865fa7eb32a"
    }
  ]
}